Key Information
If you’ve been diagnosed with the rare diseases of multiple myeloma or amyloidosis, it’s important to be evaluated by hematology experts before beginning treatment. We can help.
Karmanos’ Multiple Myeloma and Amyloidosis Specialists
Our Multiple Myeloma and Amyloidosis Multidisciplinary Team sees between 230 and 250 new multiple myeloma patients and between 30 and 50 new amyloidosis patients each year.
The team spans many disciplines, including hematologists, medical oncologists, specialized nurse practitioners, bone marrow transplant and cellular therapy specialists, radiologists, pathologists, cardiologists, nephrologists, radiation oncologists, orthopedic surgeons, population sciences and genetics specialists, and social workers. The team is entirely focused on treating multiple myeloma, amyloidosis and related conditions. Our specialists leverage their collective expertise to create a customized treatment plan for each patient.
Our team of researchers not only has vast clinical expertise, but also years of clinical research experience. We have one of the largest myeloma bone marrow transplant programs in the country and are one of the few centers in the region offering investigational cellular therapies such as CAR-T cells to patients with multiple myeloma and amyloidosis.
In fact, Karmanos has more active clinical trials for patients with multiple myeloma and amyloidosis than any other center in the state of Michigan. In many cases, patients can participate in a trial at a Karmanos Network site near where they live. The team collaborates with basic scientists to better understand multiple myeloma and amyloidosis and to bring these new therapies to the clinic.